Wasatch Biolabs宣布与安捷伦达成联合营销协议,推动原生读取靶向测序技术发展 - 医学新闻
Wasatch Biolabs announces co-marketing agreement with Agilent to advance native-read targeted sequencing - News-Medical
生物技术与制药领域的最新动态
Wasatch Biolabs announces co-marketing agreement with Agilent to advance native-read targeted sequencing - News-Medical
AGILENT TECHNOLOGIES, INC. SEC 10-K Report - TradingView — Track All Markets
Agilent Technologies : Annual Report for Fiscal Year Ending October 31, 2025 (Form 10-K) - marketscreener.com
Osaic Holdings Inc. Has $8.02 Million Stock Position in Agilent Technologies, Inc. $A - MarketBeat
Agilent Technologies opens India refurbishment center to promote sustainable science - FoodTechBiz
Perpetual Ltd Lowers Stock Position in Agilent Technologies, Inc. $A - MarketBeat
Texas Permanent School Fund Corp Trims Stake in Agilent Technologies, Inc. $A - MarketBeat
Is It Too Late To Consider Buying Agilent Technologies, Inc. (NYSE:A)? - Yahoo Finance
Agilent Technologies, Wasatch BioLabs Collaborate on Native-Read Targeted Sequencing - 富途牛牛
ABB and Agilent Technologies Enter Collaboration to Advance Laboratory Automation - MSN
Agilent Technologies, Wasatch BioLabs Collaborate on Native-Read Targeted Sequencing - marketscreener.com
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing - PR Newswire
Barclays Maintains Agilent Technologies(A.US) With Buy Rating, Maintains Target Price $165 - 富途牛牛
DNA and RNA Sample Preparation Market Is Going to Boom | Agilent - openPR.com
Agilent Technologies : Opens India Refurbishment Center to Advance Sustainable Science and Affordable Innovation - marketscreener.com
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255 - simplywall.st
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255 - simplywall.st
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255 - Sahm
Q1 EPS Forecast for Agilent Technologies Reduced by Analyst - MarketBeat
Agilent Technologies opens India Refurbishment Center to advance sustainable science and affordable innovation - Pharmabiz.com